VERADERMICS INC
MANENYSETrading Snapshot
- Day Range
- $110.46 – $112.50
- 52-Week Range
- $32.00 – $131.24
- Volume
- $2.76B
- Avg Volume
- $3.08B
- Shares Outstanding
- 41.8M
- Next Earnings
- Oct 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $644M
- Last Q Revenue
- $145M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.19
- Dividend Yield
- —
Why Investors Own MANE
- ✓High-growth profile — revenue up -4.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About VERADERMICS INC
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
NEW HAVEN, Conn., August 11, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress.
Veradermics (MANE) Positioned to Disrupt Hair Loss Market
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Veradermics (MANE) Price Target Increased by 23.12% to 166.77
Veradermics: Wait For The Post-Lockup, But Buy Before The Roll-Up
Veradermics is well-funded through the expected FDA submission in early 2027 and potential commercial launch in 2028. See why MANE stock is a Hold.
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
Veradermics Incorporated on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. The company said the treatment produced consistent hair growth, demonstrated an early onset of activity, and...
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss - Slideshow
2026-07-18. The following slide deck was published by Veradermics, Incorporated in conjunction with this event.